48th week of 2013 patent applcation highlights part 49 |
Patent application number | Title | Published |
20130316955 | AMINOSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS - The present invention relates to compounds of the formula (I) and in particular medicaments comprising at least one compound of the formula (I) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which cathepsin D is involved, in particular for use in the treatment and/or prophylaxis of arthrosis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia. | 2013-11-28 |
20130316956 | NUCLEIC ACIDS ENCODING PEPTIDES FOR TREATING WOUNDS, ANTI-ANGIOGENIC COMPOUNDS AND USES THEREOF - The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis. The peptides of the present disclosure include peptides comprising SEQ ID NOs: 1-4 which promote angiogenesis and cell proliferation. Further, the anti-angiogenic compounds of the present disclosure include antisense oligonucleotides that hybridize or are complementary to the polynucleotides of SEQ ID NOs: 5-16, and the like. | 2013-11-28 |
20130316957 | SMOOTHENED POLYPEPTIDES AND METHODS OF USE - Disclosed is an isolated or purified polypeptide or peptidomimetic comprising an amino acid sequence of a portion of a Smoothened (SMO) protein, wherein the portion comprises an amino acid sequence of any of the intracellular loops of the SMO protein, a functional fragment thereof, or a functional variant of either the portion or the functional fragment, wherein the functional fragment comprises at least 7 contiguous amino acids of the intracellular loops, and wherein the functional fragment or functional variant inhibits proliferation of a diseased cell, or a fatty acid derivative thereof. Related conjugates, nucleic acids, recombinant expression vectors, host cells, and pharmaceutical compositions are further provided. Methods of inhibiting proliferation of a diseased cell, treating or preventing cancer, treating a neoplasm or psoriasis, and inhibiting the expression of genes involved in the Hedgehog signaling pathway, thereby inhibiting the Hedgehog signaling pathway, are furthermore provided by the invention. | 2013-11-28 |
20130316958 | HIGHLY POTENT PEPTIDES TO CONTROL CANCER AND NEURODEGENERATIVE DISEASES - This invention provides compositions and method of diminishing or inhibiting autophagy by administering a FLIP protein that binds to Atg3, interfering with the formation of the LC3-Atg4-Atg7-Atg3 conjugation complex necessary for autophagy induction. This invention also provides FLIP peptide fragments that promote or induce autophagy by interfering with the activity of FLIP. | 2013-11-28 |
20130316959 | USE OF ENDOSTATIN PEPTIDES FOR THE TREATMENT OF FIBROSIS - C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung. | 2013-11-28 |
20130316960 | Novel Peptides For Treating and Preventing Immune-Related Disorders, Including Treating And Preventing Infection by Modulating Innate Immunity - In one aspect, the present invention provides isolated novel peptides that can be used to modulate innate immunity in a subject and/or for the treatment of an immune-related disorder, including treating and preventing infection by modulating innate immunity. Also provided are an agent reactive with the peptide, a pharmaceutical composition that includes the peptide, an isolated nucleic acid molecule encoding the peptide, a recombinant nucleic acid construct that includes the nucleic acid molecule, at least one host cell comprising the recombinant nucleic acid construct, and a method of producing the peptide using the host cell. The present invention further provides a method for treating and/or preventing infection in a subject by administering the peptide of the invention to the subject, thereby modulating innate immunity in the subject. Additionally, the present invention provides a method for predicting whether a subject would be responsive to treatment with a peptide of the invention. | 2013-11-28 |
20130316961 | TREATMENT OF MECP-2 ASSOCIATED DISORDERS - The invention relates to the use of cystamine, cysteamine, or a salt thereof, or of calcineurin inhibitors for treating a MeCP2-associated disorder such as Rett syndrome. | 2013-11-28 |
20130316962 | Muteins of hNGAL and related proteins with affinity for a given target - The present invention relates to novel muteins derived from human lipocalin 2 (hNGAL) and related proteins that bind a given non-natural ligand with detectable affinity. The invention also related to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. Furthermore, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein. | 2013-11-28 |
20130316963 | INNATE DEFENCE REGULATORY PEPTIDE COMPOSITIONS FOR TREATMENT OF ARTHRITIS - A composition for preventing or treating inflammatory arthritis wherein the composition comprises an innate defence regulatory peptide named IDR-1002, said peptide comprising an amino acid sequence listing of VQRWLIVWRIRK, and/or a derivative thereof and/or an analog thereof. Use of the IDR-1002 peptide and/or a derivative thereof and/or an analog or a composition comprising the peptide and/or a derivative and/or analog to modulate the expression and/or function of an inflammatory cytokine and/or a matrix metallopeptidase-3 and/or a cell-signalling pathway. | 2013-11-28 |
20130316964 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME - The disclosure provides aromatic-cationic peptide compositions and methods of preventing or treating disease using the same. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. | 2013-11-28 |
20130316965 | IDRABIOTAPARINUX FOR THE TREATMENT OF PULMONARY EMBOLISM AND FOR THE SECONDARY PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS - The invention relates to idrabiotaparinux for use in the treatment of pulmonary embolism in patients with or without deep venous thrombosis and for the secondary prevention of venous thromboembolic events in said patients, wherein the efficacy and safety of said uses are clinically proven by a phase III clinical trial. | 2013-11-28 |
20130316966 | USE OF ALBIFLORIN AND METABOLITES THEREOF - Disclosed is a use of albiflorin or a metabolite thereof in preparation of antianxiety and sleep disorder improving drugs or health-care food. Tests prove that albiflorin has significant antianxiety effects and sleep disorder improving effects achieved by prolonging SWS and low the toxic side effects, thus being a safety monomer compound capable of effectively treating anxiety and sleep disorder. | 2013-11-28 |
20130316967 | COMPOUNDS AND METHODS FOR ENHANCING ERYTHROPOIESIS - Compounds and methods for enhancing erythropoiesis. The compound contains a chemical structure of the formula (I) indicated below, in which R is a glucosyl group. In addition to having an erythropoiesis effect, the compound of the formula (I) is effective in enhancing erythropoietin formation, and increasing kidney function and expression of hepatocyte growth factor. The method includes the step of administering an effective amount of the compound of the formula (I) to a subject in need thereof and thereby results in an enhancement of erythropoiesis. | 2013-11-28 |
20130316968 | Maintenance of Platelet Inhibition During Antiplatelet Therapy - A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding. | 2013-11-28 |
20130316969 | ANTIVIRAL PHOSPHONATE ANALOGS - The invention is related to phosphorus substituted compounds with antiviral activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2013-11-28 |
20130316970 | NUCLEOTIDE ANALOGUE, METHOD OF SYNTHESIS OF NUCLEOTIDE ANALOGUE, USE OF NUCLEOTIDE ANALOGUE, ANTIVIRAL PRO-NUCLEOTIDE, PHARMACEUTICAL COMPOSITION - The object of the invention are nucleotide analogues, antiviral pro-nucleotides, a use of nucleotide analogues and pharmaceutical composition, a phosphorylating agent for synthesis of nucleotide analogue, and a method of synthesis of nucleotide analogue. More precisely, the invention applies to the new group of nucleotide analogues and their use in partial or complete inhibition of human immunodeficiency virus (HIV). | 2013-11-28 |
20130316971 | USE OF TREHALOSE FOR PREVENTION OF NEURAL TUBE DEFECTS - Maternal diabetes suppresses autophagy in neuroepithelial cells of the developing neural tube which leads to neural tube defect formation. Trehalose treatment reversed autophagy impairment and prevented neural tube defects in diabetic pregnancies. Trehalose resolved homeostatic imbalance by correcting mitochondrial defects, dysfunctional proteins, ER stress, apoptosis, and delayed neurogenesis in the neural tubes exposed to hyperglycemia. Methods of using trehalose as an intervention against hyperglycemia-induced neural tube defects are provided herein. | 2013-11-28 |
20130316972 | Prebiotic Formulations and Methods of Use - The invention provides methods and pharmaceutical compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and pharmaceutical compositions for improving overall gastrointestinal health or for decreasing symptoms of lactose intolerance by administering to subject in need thereof a pharmaceutical composition comprising a prebiotic, optionally in combination with effective amount of a probiotic microbe or microbes. The invention also provides diagnostic instruments and methods of diagnosing lactose intolerance using the diagnostic instruments. | 2013-11-28 |
20130316973 | USE OF LIPID CONJUGATES IN THE TREATMENT OF CANCER - This invention provides for the use of compounds represented by the structure of the general formula (A): | 2013-11-28 |
20130316974 | OXIDIZED REGENERATED CELLULOSE HEMOSTATIC POWDERS AND METHODS OF MAKING - The present invention is directed to hemostatic material containing compacted ORC powder comprising particles having an average aspect ratio from about 1 to about 18, wherein said compacted ORC powder have preferably been processed in a compaction device, such as a ball milled ORC powder. The present invention further relates to methods of making the hemostatic material and a method of treating a wound by applying the hemostatic powder onto and/or into the wound of a patient. | 2013-11-28 |
20130316975 | INCLUSION COMPLEXES CONTAINING PIROXICAM, A CYCLODEXTRIN AND ARGININE - The invention relates to a method for preparing a soluble inclusion complex comprising one or several active substances which are hardly soluble in an aqueous medium and are included in one or several host molecules, using the following successive stages: (a) bringing one or several active substances into contact with one or several host molecules; (b) initiating a molecular diffusion stage by bringing a dense pressurized fluid into contact with the mixture obtained in (a) in a static mode in the presence of one or several diffusing agents; (c) recovering the active substance-host molecule molecular complex formed; (d) adding and mixing an interaction agent with the active substance-host molecule molecular complex; (e) recovering the soluble inclusion compound thus formed. The invention also relates to the soluble inclusion compound obtained by the method, particularly a piroxicam-cyclodextrin-arginine compound. | 2013-11-28 |
20130316976 | PHARMACEUTICAL PREPARATION - The invention relates to a pharmaceutical formulation that contains a complex of a propofol salt with a cyclodextrin. The invention makes it possible to provide propofol in a formulation that can be stored and that can be administered intravenously without problems. | 2013-11-28 |
20130316977 | PRIMING SOLUTIONS FOR CARDIOPULMONARY BYPASS - The present invention relates to priming solutions used during cardiopulmonary bypass procedures. In particular, the present invention relates to a cardiopulmonary bypass priming solution comprising a balanced salt solution and a combination of oncotic and non-oncotic dextran molecules. The present invention also relates to the use of the priming solution in a cardiopulmonary bypass method, a method of maintaining oncotic pressure in a patient during a cardiopulmonary bypass procedure, and a combination of cardiopulmonary bypass priming solution and cardiopulmonary bypass apparatus. | 2013-11-28 |
20130316978 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF - Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents. | 2013-11-28 |
20130316979 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS - Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed. | 2013-11-28 |
20130316980 | Hypotonic Aqueous Composition with Reduced Chloride Content, With or Without Phospholipids - An aqueous composition for application in a method for surgical or therapeutic treatment of the human or animal body or in a diagnostic procedure which is practiced on the human or animal body, the composition comprising osmotically active particles and containing less than 70 μl | 2013-11-28 |
20130316981 | TERTIARY AMINES, MEDICAMENTS CONTAINING SAID AMINES, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF - The present invention relates to compounds of general formula (I) | 2013-11-28 |
20130316982 | NOVEL CRYSTALLINE FORMS - Preparation and characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans. | 2013-11-28 |
20130316983 | DRUG SCREENING METHOD, COMPOSITIONS AND METHODS OF TREATING GLAUCOMA - Methods are disclosed for treating glaucoma by treating a novel target. Methods for treating glaucoma by restoring the filtration capabilities of the endothelial lining of Schlemm's canal are provided. A method for identifying compounds capable of restoring the filtration capability of the juxtacanalicular meshwork is also provided. | 2013-11-28 |
20130316984 | Composition containing a polyorganosiloxane, a larvicide, and an organic solvent - The present invention relates to a liquid composition containing a polyorganosiloxane, a larvicide, which contains temephos, spinozad, dinetofuran, methopren, | 2013-11-28 |
20130316985 | GPR35 Ligands And Uses Thereof - A pharmaceutical composition including at least one compound of the Formulas (I), (II), or (III), or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, as defined herein. Also disclosed is a method of treatment of diseases which are pathophysiologically related to GPR35, the GPR35-hERG signaling complex, or both, as defined herein. | 2013-11-28 |
20130316986 | Anti-Thrombotic Compounds - New compounds, namely, (7aS,2′S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases. | 2013-11-28 |
20130316987 | Anti-Thrombotic Compounds - New compounds, namely, (7aS,2′S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases. | 2013-11-28 |
20130316988 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases - The present invention relates to a pharmaceutical composition useful for treating or preventing inflammatory disease and cell damage, and a method for treating or preventing inflammatory disease and cell damage. The present invention uses the 2-hydroxybenzoic acid derivative represented by the specific chemical formula or its pharmaceutically acceptable salt. The compound of the present invention is useful for treating or preventing cell damage and inflammatory disease including gastritis, gastric ulcer, pancreatitis, colitis, arthritis, diabetes, arteriosclerosis, nephritis, hepatitis, Alzheimer's disease, Parkinson's disease and Lou Gehrig's disease. | 2013-11-28 |
20130316989 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE - The invention relates to methods of treating inflammatory disease comprising administering a compound of formula A, a compound of any one of formulae 1-49 or I-III, a lipoxin compound, or an oxylipin compound. | 2013-11-28 |
20130316990 | USE OF VITAMIN D COMPOUNDS - Animal feed with 25-hydroxy vitamin D | 2013-11-28 |
20130316991 | Biologically active supplements and process of its production - The invention relates to dietary and prophylactic biologically active food supplements (BAS), in particular, from raw plant material and methods for their production; it can be used as a food supplement for human and domestic animals to reduce the cholesterol content in blood, stimulation of protein glycosylation and prophylaxis of infectious and cardiovascular diseases. | 2013-11-28 |
20130316992 | BREAST CANCER PROGNOSIS - The present invention provides gene expression profiles indicative of whether a patient afflicted with PR driven malignancies is likely to be responsive to treatment with a therapeutic compound that is an anti-progestin. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. Also, provided are methods of using gene expression profiles and assays for identifying the presence of a gene expression profile in a patient. | 2013-11-28 |
20130316993 | TRIGLYCERIDE COMPOSITIONS OF PLANT ORIGIN FOR COSMETIC APPLICATIONS OBTAINED FROM OLIVE OIL DEODORIZATION DISTILLATE - The present invention refers to a mixture of vegetable triglycerides containing saturated fatty acids with chain length C | 2013-11-28 |
20130316994 | Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors - The invention generally relates in part to methods of reducing hepatobiliary dysfunction and reducing risk of incident hepatobiliary dysfunction, comprising administering a MetAP2 inhibitor to patients in need thereof. The invention also relates in part to methods of effecting weight loss while reducing hepatic injury or risk thereof, comprising administering a MetAP2 inhibitor. | 2013-11-28 |
20130316995 | FATTY ACID CONJUGATES OF STATIN AND FXR AGONISTS; COMPOSITIONS AND METHOD OF USES - The invention relates to fatty acid statin conjugates and fatty acid FXR agonist conjugates; compositions comprising an effective amount of a fatty acid statin conjugate or a fatty acid FXR agonist conjugate; and methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid statin conjugate or a fatty acid FXR agonist conjugate. | 2013-11-28 |
20130316996 | TRANSDERMAL DELIVERY RATE CONTROL USING AMORPHOUS PHARMACEUTICAL COMPOSITIONS - A pharmaceutical composition for transdermal delivery comprising
| 2013-11-28 |
20130316997 | ANTIBACTERIAL RESIN COMPOSITION - An antibacterial resin composition comprising a thermoplastic resin or a thermosetting resin that contains a metal compound represented by the following formula (1), permitting the metal such as silver having antibacterial power to efficiently elute out and the eluted metal to remain stable as metal ions so that excellent antibacterial power can be exhibited using only a decreased amount of an expensive compound containing silver or the like, | 2013-11-28 |
20130316998 | METHOD FOR TREATING PANCREATIC CANCER - A therapeutic method for treating pancreatic cancer is disclosed comprising administering to a patient in need of treatment a gallium complex according to Formula (I) provided herein. | 2013-11-28 |
20130316999 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION - The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) | 2013-11-28 |
20130317000 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF - The invention provides novel compounds having the general formula: | 2013-11-28 |
20130317001 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF - The invention provides novel compounds having the general formula: | 2013-11-28 |
20130317002 | FUSED PYRIMIDINES - Compounds of formula (I) | 2013-11-28 |
20130317003 | Histone Deacetylase Inhibitors - This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3). | 2013-11-28 |
20130317004 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS - This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients. | 2013-11-28 |
20130317005 | NON-HYGROSCOPIC SALTS OF 5-HT2C AGONISTS - Salts of the 5-HT2C-receptor agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, and dosage forms comprising them that are useful for, inter alia, weight management. | 2013-11-28 |
20130317006 | Use of polymorphisms for identifying individuals at risk of developing autism - The present invention relates to nucleic-acid based diagnostics and the use of such diagnostics for the diagnosis of developmental disorders. Novel methods of assessing individuals for the risk of developing autism through the identification of mutations of the CFTR gene alone or in combination with other genes associated with the methylation pathways are identified. Methods of identifying those individuals that are at increased and/or decreased risk for developing autism are provided. | 2013-11-28 |
20130317007 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 - This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: | 2013-11-28 |
20130317008 | Use of a Specific Cyclic Amine Derivative or the Pharmaceutically Acceptable Salts Thereof for the Treatment or Prevention of Heart Failure - The present invention provides the use in a pharmaceutical composition of a specific cyclic amine derivative, or its pharmaceutically acceptable salts, for the treatment or prevention of heart failure of any aetiology. | 2013-11-28 |
20130317009 | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and an Anticonvulsant - The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is an anticonvulsant selected from the group consisting of retigabin, lamotrigine, lacosamide, levetiracetam, carbamazepine, sultiame, phenacemide, felbamate, topiramate, pheneturide, brivaracetam, selectracetam, zonisamide, stiripentol, beclamide, mexiletin, ralfinamide, methylphenobarbital, phenobarbital, primidone, barbexaclone, metharbital, ethotoin, phenyloin, amino(diphenylhydantoin) valeric acid, mephenyloin, fosphenyloin, paramethadione, trimethadione, ethadione, ethosuximide, phensuximide, mesuximide, clonazepam, lorazepam, diazepam, clobazam, oxcarbazepine, eslicarbazepine, rufinamide, valproic acid, valpromide, aminobutyric acid, progabide, tiagabine, and the physiologically acceptable salts thereof. | 2013-11-28 |
20130317010 | TETRAHYDROISOQUINOLINE DERIVATIVE - To provide an excellent agent for preventing or treating dementia and schizophrenia based on serotonin 5-HT | 2013-11-28 |
20130317011 | DIARYL ETHER LINKED PYRROLO [2,1-c][1,4] BENZODIAZEPINE HYBRIDS AND PROCESS FOR THE PREPARATION THEREOF - The present invention provides a compound of general formula A, useful as potential anticancer agents against eleven human cancer cell lines. The present invention further provides a process for the preparation of diaryl ether linked pyrrolo[2,1-c][1,4]benzodiazepine conjugates attached through different alkane spacers of general formula A. | 2013-11-28 |
20130317012 | METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS - Described are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (also known as Methylene Blue), the resulting (high purity) compounds, compositions comprising such compounds (e.g., tablets, capsules), and the use of such high purity compounds. The compounds are useful in inactivating pathogens, and methods of medical treatment, prophylaxis, and diagnosis of diseases including a tauopathy, related neurological and infectious diseases. | 2013-11-28 |
20130317013 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF - This invention relates to potent selective agonists of the EP | 2013-11-28 |
20130317014 | INHIBITORS OF BETA-SECRETASE - The present invention is directed to a compound represented by the following structural formula: | 2013-11-28 |
20130317015 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES - The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, | 2013-11-28 |
20130317016 | Aprepitant Injectable Formulations - An aqueous stable and ready-to-use formulation of aprepitant is prepared. Especially preferred formulations comprise a synergistic combination of a co-solvent and a surfactant and may further include a secondary co-solvent. Among other advantages of contemplated formulations, aprepitant is dissolved at high concentrations and remains dissolved and stable, even over prolonged periods of time. | 2013-11-28 |
20130317017 | PHARMACEUTICAL COMPOUNDS - Fused pyrimidines of formula (I): | 2013-11-28 |
20130317018 | Methods and Compositions for Unsilencing Imprinted Genes - The present invention provides methods and compositions for inducing expression of Ube3a in a cell by contacting the cell with a topoisomerase inhibitor. Particular embodiments include a method of treating a genomic imprinting disorder, such as Angelman syndrome, in a subject by administering to the subject an effective amount of a topoisomerase inhibitor. | 2013-11-28 |
20130317019 | A2A Antagonists as Cognition and Motor Function Enhancers - Methods are described for inducing cognition and motor function enhancement in patients suffering from Parkinson's disease by administering an effective amount of an Adenosine 2a antagonist. The Adenosine 2a antagonist can optionally be administered in combination with a dopamine precursor, such as levodopa, or a dopamine receptor agonist, | 2013-11-28 |
20130317020 | Pyridyl Derivatives as CFTR Modulators - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. | 2013-11-28 |
20130317021 | HETEROCYCLIC PYRIMIDINE CARBONIC ACID DERIVATIVES WHICH ARE USEFUL IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE - The present invention relates to a compound having the general formula (C), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, | 2013-11-28 |
20130317022 | 7-OXO-THIAZOLOPYRIDINE CARBONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE - The present invention relates to a compound having the general formula (A), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, | 2013-11-28 |
20130317023 | NOVEL PURINYLPYRIDINYLAMINO-2,4-DIFLUOROPHENYL SULFONAMIDE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION WITH INHIBITORY ACTIVITY AGAINST RAF KINASE, CONTAINING SAME AS ACTIVE INGREDIENT - A novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition with an inhibitory activity against Raf kinase, containing the same as an active ingredient are provided. The purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative of the present invention effectively regulates the activity of B-Raf kinase, and thus may be useful for preventing or treating cancers induced by the over-activation of Raf kinase, especially various melanoma, colorectal cancer, prostate cancer, thyroid cancer, ovarian cancer and the like. | 2013-11-28 |
20130317024 | PYRROLOPYRROLIDINONE COMPOUNDS - The invention relates to compounds of formula (I): | 2013-11-28 |
20130317025 | PDE-10 INHIBITORS - Vicinal substituted cyclopropyl compounds which are inhibitors of phosphodiesterase 10 are described as are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function, for example neurological, neurodegenerative and psychiatric disorders including, but not limited to, those comprising cognitive deficits or schizophrenic symptoms. | 2013-11-28 |
20130317026 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS - The present invention relates to substituted 6,5-fused bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. | 2013-11-28 |
20130317027 | COMPOUNDS AND THERAPEUTIC USES THEREOF - The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders. | 2013-11-28 |
20130317028 | C5aR ANTAGONISTS - Compounds are provided that are modulators of the C5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of C5a receptors. | 2013-11-28 |
20130317029 | OXYPYRIMIDINES AS SYK MODULATORS - The present invention is directed to compounds of formula (I) and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which arc inhibitor of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition Syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by Syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma. | 2013-11-28 |
20130317030 | Methods for Diagnosis of Cardiovascular Disease - This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure. | 2013-11-28 |
20130317031 | Nuclear Transport Modulators And Uses Thereof - The present invention relates to compounds of formula I: | 2013-11-28 |
20130317032 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to compounds of structural formula (I): | 2013-11-28 |
20130317033 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES - This invention relates to novel substituted triazolo-pyridazines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an α1-GABA | 2013-11-28 |
20130317034 | COMBINATION THERAPY FOR TREATING DIABETES - Provided is a method of treating or preventing diabetes in a subject comprising administering a therapeutically effective amount of (a) a compound of formula (I) | 2013-11-28 |
20130317036 | FOLIC ACID - RAMIPRIL COMBINATION: CELLPROTECTIVE, NEUROPROTECTIVE AND RETINOPROTECTIVE OPHTALMOLOGIC COMPOSITIONS - The invention relates to a cellprotective, neuroprotective and retinoprotective composition. In an embodiment of the invention, said composition comprises (i) Ramipril or Ramiprilate and (ii) folic acid. The composition of the invention can be used, in particular, for the prevention of loss of vision, or even for improving visual acuity and visual field in normal subjects, as well as for treating ophthalmologic pathologies, in particular: glaucoma, diabetic retinopathy, age related macular degeneration, hereditary dystrophy of the retina, uveitis, ammetropia (myopia, presbyopia). This combination of active principles could also be used in general conditions for treating general pathologies (cancer . . . ). | 2013-11-28 |
20130317037 | METHOD OF ADMINISTRATION AND TREATMENT - The present invention provides a method of treating a human with cancer comprising detecting at least one mutation in a PIK3CA gene or at least one mutant protein encoded by said PIK3CA gene from at least one first sample from said human and administering to said human an effective amount of 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide or a pharmaceutically acceptable salt thereof in a pharmaceutical composition if said at least one sample has at least one mutant PI3K protein or a mutation in the PIK3CA gene. | 2013-11-28 |
20130317038 | METHOD OF TREATING ATRIAL FIBRILLATION - The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration. | 2013-11-28 |
20130317039 | INHIBITION OF DELTA-6 DESATURASE FOR THE TREATMENT OF CARDIOMETABOLIC DISEASE - Systems and methods for screening whether a candidate compound inhibits delta-6 desaturase activity are disclosed. Also disclosed is a transgenic mammal which overexpresses a gene encoding delta-6 desaturase and an animal model of a cardiometabolic disorder or disease that includes the transgenic mammal. A method of treating a cardiometabolic disorder or disease is also disclosed. | 2013-11-28 |
20130317040 | METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS USING HIV PROTEASE INHIBITORS - The present invention is directed to a method of treating systemic lupus erythematosus (SLE) in a subject comprising administering to the subject an amount of an HIV protease inhibitor effective to treat SLE. The present invention is also directed to a pharmaceutical product comprising an HIV protease inhibitor formulated in a pharmaceutically acceptable carrier, and a package insert providing instructions for the administration of the HIV protease inhibitor for the treatment of SLE. In addition, the present invention is directed to the use of an HIV protease inhibitor for the preparation of a medicament for the treatment of SLE. | 2013-11-28 |
20130317041 | COMPOUNDS - The present invention relates to benzylpiperazine derivatives such as compounds of formula (I), which have activity as agonists of the GPR38 receptor and the use of such compounds or pharmaceutical compositions thereof in the preparation of medicaments suitable for the treatment of gastrointestinal disorders. | 2013-11-28 |
20130317042 | Method of Treating Ischemia/Reperfusion Injury - An agent for treating ischemia/reperfusion injury, including a therapeutically effective amount of a p53 agonist compound including a cis-imidazoline structure. | 2013-11-28 |
20130317043 | Compounds and Methods for Treating Autoimmune Diseases - The invention relates to a compound of Formula I: | 2013-11-28 |
20130317044 | NOVEL CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE - Carboxylic acid derivatives | 2013-11-28 |
20130317045 | THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF - Provided herein are thienopyridine and thienopyrimidine compounds of formula (I) for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions. | 2013-11-28 |
20130317046 | USE OF A DPP-4 INHIBITOR IN AUTOIMMUNE DIABETES, PARTICULARLY LADA - The present invention relates to methods for treating and/or preventing autoimmune diabetes, particularly LADA, as well as diseases related or associated therewith, comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for modifying disease trajectory of autoimmune diabetes (particularly LADA). | 2013-11-28 |
20130317047 | PHARMACEUTICAL FORMULATIONS AND USE THEREOF IN THE PREVENTION OF STROKE, DIABETES AND/OR CONGESTIVE HEART FAILURE - The present invention relates to use of an inhibitor of the renin-anglotensin system (RAS) or a pharmaceutically acceptable derivative thereof, such as ramipril or ramiprilat, in the prevention of stroke, diabetes and/or congestive heart failure (CHF). | 2013-11-28 |
20130317048 | COMBINATION COMPRISING PACLITAXEL FOR TREATING OVARIAN CANCER - The invention relates to the combination of an endothelin receptor antagonist of formula (I) | 2013-11-28 |
20130317049 | Methods Useful for the Treatment of Pain, Arthritic Conditions or Inflammation Associated with a Chronic Condition - Methods, including those for administering novel pharmaceutical compositions, dosage forms containing an opioid active pharmaceutical ingredient, are useful for treating pain, arthritic conditions and/or inflammation associated with a chronic condition, including pain from arthritis and inflammation. | 2013-11-28 |
20130317052 | QUINOLINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME - The present invention relates to a novel quinoline derivative compound, an optical isomer thereof, a pharmaceutically acceptable salt thereof, and a hydrate or a solvate thereof. The novel quinoline derivative compound, the optical isomer thereof, the pharmaceutically acceptable salt thereof, and the hydrate or the solvate thereof accelerates gastrointestinal movement, and thus can effectively prevent or treat gastrointestinal mobility disorders. | 2013-11-28 |
20130317053 | EXTERNALLY-USED DRUG FOR TREATING SKIN DISORDER AND METHOD FOR PRODUCING SAME - An external medicine of the present invention includes a gel composition or an ointment composition, each of which contains sirolimus and/or a derivative thereof. Accordingly, provided is an external medicine which enables sirolimus, in an amount sufficient to treat a skin disease, to be absorbed into an affected part without causing a side effect. | 2013-11-28 |
20130317054 | NEURONAL NICOTINIC AGONIST AND METHODS OF USE - An embodiment relates to a selective agonist of neuronal nicotinic acetylcholine receptor α7 subtype, a pharmaceutically suitable salt, prodrug, or a metabolite thereof, for the prevention and treatment of diseases and conditions that are mediated by nicotinic acetylcholine receptors, and methods of use thereof. Another embodiment is a method of administering a pharmaceutically effective amount of a selective agonist of neuronal nicotinic acetylcholine receptor α7 subtype, or a pharmaceutically suitable salt, prodrug, or a metabolite thereof, to a mammal in need thereof. | 2013-11-28 |
20130317055 | NEURONAL NICOTINIC AGONIST AND METHODS OF USE - An embodiment relates to a selective agonist of neuronal nicotinic acetylcholine receptor α7 subtype, a pharmaceutically suitable salt, prodrug, or a metabolite thereof, for the prevention and treatment of diseases and conditions that are mediated by nicotinic acetylcholine receptors, and methods of use thereof. Another embodiment is a method of administering a pharmaceutically effective amount of a selective agonist of neuronal nicotinic acetylcholine receptor α7 subtype, a pharmaceutically suitable salt, prodrug, or a metabolite thereof, to a mammal in need thereof. | 2013-11-28 |
20130317056 | NEURONAL NICOTINIC AGONISTS AND METHODS OF CORRELATING COMT SNPS - This application is directed to a-neuronal nicotinic receptor agonists selective for α7-subtype that are useful for improving cognition impairment in patients having schizophrenia, a schizophreniform disorder or a related schizophrenia spectrum psychotic disorder. Compounds and compositions containing such compounds, and methods of using such compound and compositions are described herein. | 2013-11-28 |
20130317057 | ALDOSTERONE SYNTHASE INHIBITORS - The invention involves compounds of structural Formula (I) and the pharmaceutically acceptable salts thereof. The compounds of the invention are effective at selectively inhibiting CYP11B2, and are therefore useful for the treatment or prophylaxis of disorders that are associated with elevated aldosterone levels, including, but not limited to, hypertension and heart failure. | 2013-11-28 |